These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 8281624)

  • 1. Combination chemotherapy of human ovarian xenografts with intraperitoneal liposome-incorporated valinomycin and cis-diamminedichloroplatinum(II).
    Daoud SS
    Cancer Chemother Pharmacol; 1994; 33(4):307-12. PubMed ID: 8281624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced toxicity and enhanced antitumor effects in mice of the ionophoric drug valinomycin when incorporated in liposomes.
    Daoud SS; Juliano RL
    Cancer Res; 1986 Nov; 46(11):5518-23. PubMed ID: 3756900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic cytotoxic actions of cisplatin and liposomal valinomycin on human ovarian carcinoma cells.
    Daoud SS; Forde NH
    Cancer Chemother Pharmacol; 1991; 28(5):370-6. PubMed ID: 1914081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro interaction of liposomal valinomycin and platinum analogs: cytotoxic and cytokinetic effects.
    Daoud SS; Sakata MK
    Anticancer Drugs; 1993 Aug; 4(4):479-86. PubMed ID: 8400351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracavitary therapy of murine ovarian cancer with cis-diamminedichloroplatinum(II) and 10-ethyl-10-deazaaminopterin incorporating systemic leucovorin protection.
    Sirotnak FM; Schmid FA; DeGraw JI
    Cancer Res; 1989 Jun; 49(11):2890-3. PubMed ID: 2785847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effects of pirarubicin and epirubicin in combination with doxifluridine and cisplatin against mouse P388 leukemia.
    Agata N; Mase T; Izumi H; Hirano S; Iguchi H; Tone H; Takeuchi T
    Cancer Biochem Biophys; 1995 Nov; 15(2):95-101. PubMed ID: 8590441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitisation of human ovarian carcinoma cells to cis-diamminedichloroplatinum (II) by amphotericin B in vitro and in vivo.
    Kojima M; Kikkawa F; Oguchi H; Mizuno K; Maeda O; Tamakoshi K; Ishikawa H; Kawai M; Suganuma N; Tomoda Y
    Eur J Cancer; 1994; 30A(6):773-8. PubMed ID: 7917536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming cis-diamminedichloroplatinum (II) resistance of human ovarian tumor cells by combination treatment with cis-diamminedichloroplatinum (II) and tumor necrosis factor-alpha.
    Mizutani Y; Bonavida B
    Cancer; 1993 Aug; 72(3):809-18. PubMed ID: 8334635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Combination therapy of a new platinum complex, DWA2114R with various antitumor agents against mouse tumors in vivo].
    Akamatsu K; Endo K; Tsunenari T; Matsumoto T; Kaiho S; Morikawa K; Koizumi M; Mitsui H; Koizumi K
    Gan To Kagaku Ryoho; 1992 Feb; 19(2):229-35. PubMed ID: 1736835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152).
    Fujimoto K; Oka T; Morimoto M
    Cancer Res; 1987 Mar; 47(6):1516-22. PubMed ID: 2434218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
    Elliott WL; Roberts BJ; Howard CT; Leopold WR
    Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of thymidine on the toxicity and antitumor activity of cis-diamminedichloroplatinum (II).
    Grossie VB; Valdivieso M; Drewinko B; Loo TL
    Cancer Chemother Pharmacol; 1984; 13(1):27-30. PubMed ID: 6539657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination chemotherapy with paclitaxel and intraperitoneal cisplatin for ovarian cancer with disseminated lesions in the peritoneum and the diaphragm.
    Terauchi F; Moritake T; Yamamoto Y; Ogura H
    Int J Clin Oncol; 2002 Dec; 7(6):356-60. PubMed ID: 12494251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
    Garofalo A; Naumova E; Manenti L; Ghilardi C; Ghisleni G; Caniatti M; Colombo T; Cherrington JM; Scanziani E; Nicoletti MI; Giavazzi R
    Clin Cancer Res; 2003 Aug; 9(9):3476-85. PubMed ID: 12960140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combined effect of CDDP with various types of antitumor drugs against P 388 leukemia].
    Uchida T; Nishikawa K; Shibasaki C; Okamoto K; Arakawa M; Ekimoto H; Takahashi K
    Gan To Kagaku Ryoho; 1989 Jun; 16(6):2275-82. PubMed ID: 2735770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effects of three platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-platinum (II) monohydrate (DWA2114R), cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) and cis-diamminedichloroplatinum(II) (CDDP), in mice.
    Endo K; Akamatsu K; Matsumoto T; Morikawa K; Koizumi M; Mitsui H; Koizumi K
    Anticancer Res; 1992; 12(1):49-58. PubMed ID: 1567181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different interaction of cisplatin and etoposide on in vivo and in vitro tumor systems.
    Soranzo C; Pratesi G; Zunino F
    Anticancer Drugs; 1990 Oct; 1(1):23-8. PubMed ID: 2131031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand combined with cisplatin in ovarian carcinoma cell lines in vitro and in vivo.
    Liu P; Mao H; Hou P
    Int J Gynecol Cancer; 2006; 16(2):538-48. PubMed ID: 16681723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete inhibition of human ovarian cancer xenografts in nude mice by suramin and cis-diamminedichloroplatinum(II).
    Kikuchi Y; Hirata J; Hisano A; Tode T; Kita T; Nagata I
    Gynecol Oncol; 1995 Jul; 58(1):11-5. PubMed ID: 7789875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of therapeutic effectiveness by combining liposomal honokiol with cisplatin in ovarian carcinoma.
    Liu Y; Chen L; He X; Fan L; Yang G; Chen X; Lin X; DU L; Li Z; Ye H; Mao Y; Zhao X; Wei Y
    Int J Gynecol Cancer; 2008; 18(4):652-9. PubMed ID: 17892458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.